- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07704658
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
7 augusti 2026 uppdaterad av: Rigel Pharmaceuticals
A Multi-center, Open-label, Drug-drug Interaction Study to Evaluate the Effect of Pralsetinib (Gavreto) on the Pharmacokinetics of CYP3A4, CYP2C8, and CYP2C9 Substrates, and Hormones Estradiol/Norethisterone Acetate in Patients With Advanced or Metastatic Solid Tumors
An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with rearranged during transfection (RET) fusion- or mutation-positive solid tumors
Studieöversikt
Status
Rekrytering
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Beräknad)
12
Fas
- Fas 4
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Kay Patel
- Telefonnummer: (650) 624-1100
- E-post: kpatel@rigel.com
Studieorter
-
-
-
Madrid, Spanien, 28050
- Rekrytering
- Hospital Universitario HM Sanchinarro
-
Kontakt:
- Irene Moreno, MD
- E-post: irene.moreno@startmadrid.com
-
-
La Rioja
-
Logroño, La Rioja, Spanien, 26006
- Rekrytering
- Hospital Universitario San Pedro
-
Kontakt:
- Maria De Miguel, MD, PhD, MBA
- E-post: maria.demiguel@startrioja.com
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Must be willing and able to participate and comply with all study requirements and to provide signed and dated written informed consent
- Adult male or female ≥ 18 years of age at the time of signing the informed consent form.
- Must have a body mass index (BMI) ≥ 18 and ≤ 32 kg/m² and a minimum body weight of 50 kg at screening.
- Must have an Eastern Cooperative Oncology Group performance status ≤ 2.
- Must have recovered from the non-hematologic toxic effects of prior treatment to Grade ≤ 1, or baseline value (excluding infertility, alopecia, or Grade 1 neuropathy)
- Must have a confirmed diagnosis of advanced or metastatic solid tumor that has relapsed after, or is not responsive to, standard therapies and harbors an oncogenic RET fusion or mutation as determined by a validated test.
Must have adequate organ function, defined by the following:
- Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹/L.
- Platelet count ≥ 75 × 10⁹/L.
- Hemoglobin ≥ 9 g/dL.
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN), or ≤ 5 × ULN in patients with known liver metastases.
- Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN in patients with Gilbert syndrome).
- Creatinine clearance ≥ 40 mL/min using the Cockcroft-Gault equation.
- Serum phosphorus ≤ 5.5 mg/dL.
- International normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (aPTT) within normal laboratory limits.
- Must be at least 4 weeks from major surgery, radiotherapy, chemotherapy, immunotherapy, kinase/targeted therapy, or gene therapy prior to the first dose of study treatment and recovered from treatment-related toxicities to ≤ Grade 1 (excluding alopecia). Must be ≥ 6 weeks since last treatment if they received a long-acting agent such as a nitrosourea, mitomycin, or monoclonal antibodies. In general, a treatment interval of two half-lives should be considered and discussed with the Sponsor. (Concurrent cancer therapy of any type is not permitted).
- Female patients may participate if they are not of childbearing potential (e.g., surgically sterile or postmenopausal).
- Male patients with female partners of childbearing potential must agree to use highly effective contraception during study treatment and for 90 days after the last dose of study treatment.
- Male patients must refrain from sperm donation during study treatment and for 90 days after the last dose of study treatment.
Exclusion Criteria:
- Clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, electrocardiogram (ECG), or laboratory tests at screening that, in the investigator's judgment, are likely to interfere with the objectives of the trial or the safety of the patient.
- Surgery (e.g., gastric bypass) or medical condition that may significantly affect absorption of study medications, as judged by the investigator.
- History of pneumonitis within the last 12 months.
- History of active or latent tuberculosis (TB), regardless of treatment history, or a positive screening test for latent Mycobacterium tuberculosis infection by QuantiFERON® TB Gold. Indeterminate results may be confirmed by repeat testing or by a purified protein derivative (PPD) skin test.
- Serious infection requiring intravenous or systemic antibiotics within 7 days prior to initiation of study treatment, or any active infection that, in the opinion of the investigator, could impact patient safety (e.g., COVID-19 or influenza).
Clinically significant, uncontrolled cardiovascular disease, including:
- New York Heart Association (NYHA) Class III or IV congestive heart failure.
- Myocardial infarction or unstable angina within the previous 6 months, clinically significant uncontrolled arrhythmias, including bradyarrhythmias that may cause QT prolongation (e.g., second- or third-degree heart block).
- Uncontrolled hypertension (i.e., mean systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg on 3 repeated measurements) or clinically significant hypotension (i.e., systolic blood pressure <90 mmHg and/or diastolic blood pressure <50 mmHg) or severe episodes of orthostatic hypotension.
- History of prolonged QT syndrome or torsades de pointes, or familial history of long QT syndrome.
- QTcF ≥470 ms on at least 2 ECGs performed >30 minutes apart.
- Central nervous system (CNS) metastases or primary CNS tumor.
- Use of systemic corticosteroids within 4 weeks prior to first dose of study treatment.
- More than 30 Gy of radiotherapy to the lung within 6 months prior to check-in.
- History of multiple and/or severe allergies to drugs or foods, or history of severe anaphylactic reaction.
- Use of prohibited medications or procedures
- Medical conditions, treatments, or underlying diseases that constitute contraindications to the use of study substrates or probe drugs
- Ingestion of alcohol within 72 hours prior to first study drug administration and during the study period.
- Participation in another investigational drug trial within 30 days prior to study drug administration (or within 5 half-lives of the investigational drug, whichever is longer) or exposure to more than 3 investigational agents within 12 months prior to study drug administration.
- Positive serology for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody at screening (a negative PCR test overrides a positive serology).
- Positive human immunodeficiency virus (HIV) test at screening.
- Positive urine drug screen (unless attributable to concomitant medication) or positive alcohol breath test at screening and/or Day -1.
- Patients who are legally incapacitated, have limited legal capacity, or are otherwise considered vulnerable.
- Female patients who are pregnant or breastfeeding.
- Patients who plan to become pregnant or father a child (including ova or sperm donation) during the study or within 3 months after the last dose of study drug.
- Known allergy or history of hypersensitivity to study drug(s) or their excipients.
- Concomitant use of strong or moderate CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and/or CYP3A4 inhibitors within 7 days or 5 half-lives (whichever is longer) prior to first dose of study treatment.
- Concomitant use of strong or moderate CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and/or CYP3A4 inducers within 14 days or 5 half-lives (whichever is longer) prior to first dose of study treatment.
- History of or active clinically significant cardiovascular, respiratory, gastrointestinal, renal, hepatic, neurological, psychiatric, musculoskeletal, genitourinary, dermatologic, hematologic, or other disorder that, in the investigator's judgment, could interfere with study participation or the absorption, metabolism, or excretion of study treatment.
- History of prior second malignancy unless disease-free for ≥ 12 months or considered surgically cured. Patients with nonmelanoma skin cancers or with carcinomas in situ at any time following curative intent surgery and low grade, early-stage prostate cancer (Gleason score 6 or below, stage 1 or 2) with no requirement for therapy at any time prior to the study, or previously resected are also eligible.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Pralsetinib with CYP450 Probe Substrates and Hormonal Contraceptive
|
Pralsetinib 400mg orally (PO) once daily (QD) from Day 4 to Day 10, with an option to continue up to Day 33
Midazolam, repaglinide, and losartan (CYP probe substrates) and, for female participants, estradiol/norethisterone acetate (hormonal probe substrate), administered orally (PO) once on Day 1 and once on Day 9.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Area Under the Plasma Concentration-Time Curve from zero to infinity (AUC0-inf)
Tidsram: Up to 48 hours post-dose or as appropriate for each probe substrate
|
To evaluate the effect of pralsetinib on the overall exposure of CYP3A4, CYP2C8, and CYP2C9, probe substrates, and hormonal contraceptive by measuring AUC0-inf for each probe substrate and its relevant metabolites.
|
Up to 48 hours post-dose or as appropriate for each probe substrate
|
|
Area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUClast)
Tidsram: Up to 48 hours after each probe drug administration
|
To evaluate the effect of pralsetinib on the overall exposure of CYP3A4, CYP2C8, and CYP2C9 probe substrates, and hormonal contraceptive by measuring AUClast for each probe substrate and its relevant metabolites.
|
Up to 48 hours after each probe drug administration
|
|
Maximum Peak Plasma Concentration (Cmax)
Tidsram: Up to 48 hours after each probe drug administration
|
To evaluate how pralsetinib affects the peak levels of probe substrates, and hormonal contraceptive, in the blood after they are taken alone and again after treatment with pralsetinib
|
Up to 48 hours after each probe drug administration
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Time to Maximum Plasma Concentration (tmax)
Tidsram: Up to 48 hours after each probe drug administration
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to assess how pralsetinib affects the time required to reach peak plasma concentration for each probe drug.
|
Up to 48 hours after each probe drug administration
|
|
Terminal Half-Life (t½)
Tidsram: Up to 48 hours after each probe drug administration
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization To evaluate the effect of pralsetinib on the terminal half-life of each probe drug
|
Up to 48 hours after each probe drug administration
|
|
Percent of Area Under the plasma concentration-time curve obtained at extrapolation (%AUCex)
Tidsram: Up to 48 hours after each probe drug administration
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to determine the proportion of the AUC that is extrapolated, providing insight into pralsetinib's effect on drug elimination
|
Up to 48 hours after each probe drug administration
|
|
Mean residence time (MRT)
Tidsram: Up to 48 hours after each probe drug administration
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to assess how pralsetinib affects the average time each probe drug remains in the body
|
Up to 48 hours after each probe drug administration
|
|
Terminal Elimination Rate Constant (λz)
Tidsram: Up to 48 hours after each probe drug administration
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to assess how pralsetinib affects the terminal elimination rate constant of each probe drug
|
Up to 48 hours after each probe drug administration
|
|
Apparent Total Body Clearance (CL/F)
Tidsram: Up to 48 hours after each probe drug administration
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to evaluate the effect of pralsetinib on the apparent total body clearance of each probe drug
|
Up to 48 hours after each probe drug administration
|
|
Apparent Volume of Distribution (Vz/F)
Tidsram: Up to 48 hours after each probe drug administration
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to assess how pralsetinib influences the apparent volume of distribution of each probe drug
|
Up to 48 hours after each probe drug administration
|
|
Safety and Tolerability
Tidsram: From the start of treatment through approximately 30 days after the last dose of study treatment
|
Incidence, frequency, relatedness, and severity of treatment-emergent adverse events (TEAEs) associated with co-administration of pralsetinib and probe substrates
|
From the start of treatment through approximately 30 days after the last dose of study treatment
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
4 mars 2026
Primärt slutförande (Beräknad)
30 juli 2027
Avslutad studie (Beräknad)
30 augusti 2027
Studieregistreringsdatum
Först inskickad
9 juli 2026
Först inskickad som uppfyllde QC-kriterierna
9 juli 2026
Första postat (Faktisk)
15 juli 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
10 augusti 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
7 augusti 2026
Senast verifierad
1 augusti 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Sjukdomar i det endokrina systemet
- Neoplasmer efter plats
- Luftvägssjukdomar
- Lungsjukdomar
- Neoplasmer i endokrina körtel
- Neoplasmer i huvud och hals
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Lungneoplasmer
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Sköldkörtelsjukdomar
- Neoplasmer
- Karcinom, icke-småcellig lunga
- Sköldkörtelneoplasmer
- Aminosyror, peptider och proteiner
- Proteiner
- Enzymer
- Enzymer och koenzymer
- Oxidoreduktaser
- Cytokromer
- Blandade syresyror
- Syreaser
- Hemeproteiner
- Arylhydroxylaser
- Cytochrom P-450-enzymsystemet
- Cytochrom P450-familj 2
- Oxidoreduktaser som verkar på CH-NH-gruppdonatorer
- Cytochrom P450-familj 3
- Oxidoreduktaser, N-demetylerande
- pralinib
- Cytochrom P-450 CYP2C8
- Cytochrom P-450 CYP3A
Andra studie-ID-nummer
- RGL-RET-001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Ja
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
produkt tillverkad i och exporterad från U.S.A.
Ja
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .